195 related articles for article (PubMed ID: 16136164)
1. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.
Hellebrand E; Mautner J; Reisbach G; Nimmerjahn F; Hallek M; Mocikat R; Hammerschmidt W
Gene Ther; 2006 Jan; 13(2):150-62. PubMed ID: 16136164
[TBL] [Abstract][Full Text] [Related]
2. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
Suzuki T; Piche A; Kasono K; Xiang J; Gomez-Navarro J; Moriuchi S; Krisky DM; Oligino T; Glorioso JC; Curiel TJ; Curiel DT
Biochem Biophys Res Commun; 1998 Nov; 252(3):686-90. PubMed ID: 9837767
[TBL] [Abstract][Full Text] [Related]
3. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
[TBL] [Abstract][Full Text] [Related]
4. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells.
Mũcke S; Polack A; Pawlita M; Zehnpfennig D; Massoudi N; Bohlen H; Doerfler W; Bornkamm G; Diehl V; Wolf J
Gene Ther; 1997 Feb; 4(2):82-92. PubMed ID: 9081710
[TBL] [Abstract][Full Text] [Related]
5. Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.
Hettich E; Janz A; Zeidler R; Pich D; Hellebrand E; Weissflog B; Moosmann A; Hammerschmidt W
Gene Ther; 2006 May; 13(10):844-56. PubMed ID: 16421600
[TBL] [Abstract][Full Text] [Related]
6. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
7. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
8. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
9. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
10. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T
Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811
[TBL] [Abstract][Full Text] [Related]
11. Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins.
Li L; Wickham TJ; Keegan AD
Gene Ther; 2001 Jun; 8(12):938-45. PubMed ID: 11426334
[TBL] [Abstract][Full Text] [Related]
12. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
13. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
14. A herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy.
Stevenson AJ; Frolova-Jones E; Hall KT; Kinsey SE; Markham AF; Whitehouse A; Meredith DM
Cancer Gene Ther; 2000 Jul; 7(7):1077-85. PubMed ID: 10917211
[TBL] [Abstract][Full Text] [Related]
15. B cells under influence: transformation of B cells by Epstein-Barr virus.
Küppers R
Nat Rev Immunol; 2003 Oct; 3(10):801-12. PubMed ID: 14523386
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-based vector improves the tumor cell killing effect of pituitary tumor in HVJ-liposome-mediated transcriptional targeting suicide gene therapy.
Izumo T; Ohtsuru A; Tokunaga Y; Namba H; Kaneda Y; Nagata I; Yamashita S
Int J Oncol; 2007 Aug; 31(2):379-87. PubMed ID: 17611695
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
19. Recognition of endogenously synthesized HLA-DR4 restricted HCV epitopes presented by autologous EBV transformed B-lymphoblastoid cell line.
Yang M; Zhu F; Sønderstrup G; Eckels DD
Vaccine; 2005 Jan; 23(7):951-62. PubMed ID: 15603898
[TBL] [Abstract][Full Text] [Related]
20. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
